HematologyPub Date : 2026-12-31Epub Date: 2026-04-17DOI: 10.1080/16078454.2026.2659974
Xiao-Lin Liu, Xin-Xin He, Mei-Jiao Li, Mei Guo, Dan Li, Xiao-Dong Xu
{"title":"Quality of life among older adults undergoing hematopoietic stem cell transplantation: a narrative review.","authors":"Xiao-Lin Liu, Xin-Xin He, Mei-Jiao Li, Mei Guo, Dan Li, Xiao-Dong Xu","doi":"10.1080/16078454.2026.2659974","DOIUrl":"10.1080/16078454.2026.2659974","url":null,"abstract":"<p><strong>Introduction: </strong>With the global aging population and the expanded application of hematopoietic stem cell transplantation (HSCT) in older adults, understanding quality of life (QOL) outcomes in this vulnerable group is of paramount importance.</p><p><strong>Objectives: </strong>This narrative review synthesizes current evidence to (1) describe the trajectory of QOL in older HSCT recipients; (2) identify the key transplant-related, physiological, and psychosocial determinants of post-transplant well-being; and (3) evaluate existing and emerging strategies to improve patient outcomes.</p><p><strong>Methods: </strong>A literature search was conducted in PubMed/MEDLINE, Web of Science, and Embase (inception to December 2024) using terms related to HSCT, older adults, and QOL. Articles focusing on patients aged ≥60 years were selected to synthesize evidence on QOL outcomes, influencing factors, and interventions.</p><p><strong>Results: </strong>Older adults experience significant QOL decline, typically nadiring within three months post-transplant, with infrequent full recovery to baseline. Key determinants include transplant modality (allogeneic vs. autologous), regimen intensity, and complications like graft-versus-host disease. These interact with patient-specific factors such as frailty, nutritional status, psychological distress, and social support. Emerging multidisciplinary strategies, including optimized conditioning regimens, structured psychosocial support, and geriatric assessment-informed enhanced recovery programs, show promise in mitigating QOL impairment.</p><p><strong>Discussion: </strong>The evidence highlights the multifactorial nature of QOL in this population. A critical gap remains the lack of standardized, HSCT-specific geriatric assessment tools to guide personalized interventions. While multidisciplinary care is advocated, its components require further refinement and validation for older adults.</p><p><strong>Conclusion: </strong>A holistic, patient-centered approach integrating geriatric principles is essential to improve long-term survivorship and QOL in the growing population of older adults undergoing HSCT.</p>","PeriodicalId":13161,"journal":{"name":"Hematology","volume":"31 1","pages":"2659974"},"PeriodicalIF":2.0,"publicationDate":"2026-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147716954","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Probable sarcopenia and bone health in transfusion-dependent beta thalassemia patients.","authors":"Sevil Sadri, Nazif Yalcin, Serkan Guven, Aysegul Ertinmaz, Nizameddin Koca, Vildan Gursoy","doi":"10.1080/16078454.2026.2712127","DOIUrl":"https://doi.org/10.1080/16078454.2026.2712127","url":null,"abstract":"<p><strong>Objectives: </strong>Low bone mass is common in adults with transfusion-dependent thalassemia (TDT). While sarcopenia contributes to frailty, studies examining its association with falls and fractures in TDT remain limited. This study aimed to determine the prevalence of probable sarcopenia in adults with transfusion-dependent thalassemia and to identify related risk factors.</p><p><strong>Methods: </strong>This cross-sectional study included 45 adult TDT patients followed at Bursa City Hospital Hematology Clinic between September 2023 and September 2024, and 40 age- and sex-matched healthy controls. Bone mineral density (BMD) was assessed per Turkish Endocrinology Osteoporosis Guidelines and classified as normal, osteopenia, or osteoporosis. Probable sarcopenia was evaluated according to EWGSOP2 criteria based on handgrip strength measurements[14]. Anthropometric data and biochemical parameters were recorded.</p><p><strong>Results: </strong>Eighty-five participants (52.9% TDT, 47.1% controls) were evaluated. The mean BMI was 21.6 ± 1.99 kg/m<sup>2</sup>. No significant differences were observed in calcium, vitamin D levels (<i>p</i> = 0.492, <i>p</i> = 0.068, <i>p</i> = 0.911, respectively). Handgrip strength was significantly lower in TDT patients (24.96 ± 12.75 kg) than in controls (33.9 ± 15.39kg; <i>p</i> = 0.004). Probable sarcopenia was identified in 13.3% of patients and in none of the controls (<i>p</i> = 0.027).</p><p><strong>Discussion: </strong>Routine screening for probable sarcopenia should be incorporated into fracture prevention strategies for TDT, particularly among osteoporotic individuals. Therefore, the findings of this study should be interpreted as exploratory observations rather than confirmatory evidence.</p><p><strong>Conclusion: </strong>Probable sarcopenia was identified in a subset of adult patients with TDT based on reduced handgrip strength according to EWGSOP2 criteria. Future longitudinal and multicenter studies incorporating muscle mass and functional performance measurements are required to confirm these findings.</p>","PeriodicalId":13161,"journal":{"name":"Hematology","volume":"31 1","pages":"2712127"},"PeriodicalIF":2.0,"publicationDate":"2026-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148669231","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
HematologyPub Date : 2026-12-31Epub Date: 2026-07-10DOI: 10.1080/16078454.2026.2700811
Abdullah M Alrajhi, Bashayer Alshehri, Walaa A Alshahrani, Arwa AlHaj Issa, Amal H Alotaibi, Areej Abumustafa, Ghadah Alyousif, Nora Alkhudair, Mai Alalawi, Nada Alsuhebany, Mohammed Alzahrani, Abrar Alghamdi, Ramesh Vishwakarma, Abrar Bakr, Zahra AlHaj Issa, Abdullah Alateeq, Abeer Ageel Alenazi, Mashael S Alaboud, Badr Alayaf, Homood M As Sobeai, Khalid Al Sulaiman
{"title":"Effectiveness and safety of brentuximab vedotin-containing regimen versus standard chemotherapy in relapsed or refractory Hodgkin lymphoma: a multicenter cohort study.","authors":"Abdullah M Alrajhi, Bashayer Alshehri, Walaa A Alshahrani, Arwa AlHaj Issa, Amal H Alotaibi, Areej Abumustafa, Ghadah Alyousif, Nora Alkhudair, Mai Alalawi, Nada Alsuhebany, Mohammed Alzahrani, Abrar Alghamdi, Ramesh Vishwakarma, Abrar Bakr, Zahra AlHaj Issa, Abdullah Alateeq, Abeer Ageel Alenazi, Mashael S Alaboud, Badr Alayaf, Homood M As Sobeai, Khalid Al Sulaiman","doi":"10.1080/16078454.2026.2700811","DOIUrl":"10.1080/16078454.2026.2700811","url":null,"abstract":"<p><strong>Objective: </strong>Hodgkin lymphoma (HL) constitutes 3.4% of all cancers in Saudi Arabia, with advanced-stage relapse rates reaching 40%. While the anti-CD30 agent brentuximab vedotin (BV) has established efficacy, local data are limited. This study aims to assess the real-world effectiveness and safety of Brentuximab vedotin (BV)-containing regimens compared to non-BV regimens in relapsed or refractory classical Hodgkin lymphoma (cHL) in Saudi Arabia.</p><p><strong>Methods: </strong>A retrospective, multicenter cohort study was conducted including 93 adult patients with relapsed or refractory cHL in Saudi Arabia between 2016 and 2021. Patients were categorized into a BV-containing group (n = 61) and a control group (n = 32). The outcomes were overall response rate (ORR), complete response (CR), event-free survival (EFS), and post-chemotherapy complications.</p><p><strong>Results: </strong>= The BV group showed a higher ORR compared to the non-BV group (82.5% vs. 76.9%), although this difference was not statistically significant (adjusted odds ratio [aOR] = 9.09; 95% CI = 0.67-122.57; <i>P</i> = 0.10). CR rates were comparable between the two groups, at 59.6% in the BV group vs. 61.5% in the control group (aOR = 1.86; 95% CI = 0.24-14.46; <i>P</i> = 0.55). EFS was significantly longer in the BV group compared with the control group in the crude analysis (22.5 vs. 11.2 months; <i>P</i> = 0.03); however, this finding did not reach statistical significance in the regression analysis (beta coefficient = 7.04; 95% CI = -2.96 to 17.03; <i>P </i>= 0.18). Post-chemotherapy complications were comparable and not statistically significant across both groups.</p><p><strong>Conclusion: </strong>The research indicates that BV may offer a potential clinical advantage for patients with relapsed or refractory cHL. To validate these findings and optimize treatment strategies for this population, larger long-term studies with expanded patient cohorts are required.</p>","PeriodicalId":13161,"journal":{"name":"Hematology","volume":"31 1","pages":"2700811"},"PeriodicalIF":2.0,"publicationDate":"2026-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148420972","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Effects of long-term cryopreservation at -80 °C on the viability and recovery of peripheral blood stem cells.","authors":"Tomoaki Akagi, Toru Ebina, Fuyuki Meguro, Mitsuki Sakamoto, Tomoko Nihonyanagi, Takuto Tachita, Kohmei Kubo","doi":"10.1080/16078454.2026.2741981","DOIUrl":"https://doi.org/10.1080/16078454.2026.2741981","url":null,"abstract":"<p><strong>Objectives: </strong>Ensuring the long-term stability of cryopreserved peripheral blood stem cells (PBSCs) is critical for optimal patient outcomes. However, it remains unclear how long-term cryopreservation at -80 °C without controlled-rate freezing in a mechanical freezer affects these cells. Temperature changes may damage cells, reducing their viability. Therefore, in this study, we investigated the effects of long-term storage and the presence of other cells on the viability and recovery of cryopreserved PBSCs.</p><p><strong>Methods: </strong>Autologous and allogeneic PBSC samples (<i>n</i> = 115) were cryopreserved at -80 °C in a mechanical freezer without controlled-rate freezing. Subsequently, CD34<sup>+</sup> cell viability and recovery were evaluated after storage for up to 60 months using flow cytometry. The effects of co-existing blood cells on the cryopreservation of CD34<sup>+</sup> cells were also examined.</p><p><strong>Results: </strong>Cryopreservation for <24 months did not significantly reduce the viability and recovery of CD34<sup>+</sup> cells, while decreases were observed following storage for >24 months. Further, cryopreservation with ≥10% granulocytes decreased CD34<sup>+</sup> cell viability and recovery.</p><p><strong>Discussion: </strong>The present findings suggest that storage beyond 24 months and containing a high proportion of granulocytes may have a negative impact on CD34⁺ cell viability and recovery. Attention to storage duration and contaminating cell populations could help support more stable outcomes during cryopreservation at -80 °C.</p><p><strong>Conclusions: </strong>The cryopreservation conditions employed in this study did not significantly reduce CD34<sup>+</sup> cell viability and recovery during storage for up to 24 months. A higher granulocyte content was associated with lower post-thaw CD34<sup>+</sup> viability and recovery.</p>","PeriodicalId":13161,"journal":{"name":"Hematology","volume":"31 1","pages":"2741981"},"PeriodicalIF":2.0,"publicationDate":"2026-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149080462","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
HematologyPub Date : 2026-12-31Epub Date: 2026-11-02DOI: 10.1080/16078454.2026.2755117
Fan Chao, Rongwei Li
{"title":"Hetrombopag in China: expanding indications, comparative positioning, and risk management - a critical narrative review.","authors":"Fan Chao, Rongwei Li","doi":"10.1080/16078454.2026.2755117","DOIUrl":"https://doi.org/10.1080/16078454.2026.2755117","url":null,"abstract":"<p><strong>Objectives: </strong>Hetrombopag is an oral nonpeptide thrombopoietin receptor agonist approved only in China. We critically appraised evidence across approved and investigational indications, compared it with other thrombopoietin receptor agonists, and assessed clinically relevant safety and risk management.</p><p><strong>Methods: </strong>PubMed/MEDLINE, the Cochrane Library, ClinicalTrials.gov, CNKI, and Wanfang were searched from inception through 18 October 2026, with citation tracing and regulatory/guideline review. Evidence was ranked by design and publication status.</p><p><strong>Results: </strong>A Chinese phase III adult immune thrombocytopenia trial reported week-8 platelet responses of 58.9% and 64.3% with two starting doses versus 5.9% with placebo. In refractory severe aplastic anemia, a single-arm phase II study reported week-18 hematologic response in at least one lineage of 41.8% (95% confidence interval 28.7-55.9). Randomized trials also underpin 2026 Chinese approvals for chronic immune thrombocytopenia in patients aged at least 6 years and adult solid-tumor treatment-induced thrombocytopenia; however, the pivotal phase III solid-tumor report remained a conference abstract and international validation was pending. No randomized head-to-head trial establishes superiority over eltrombopag, avatrombopag, or romiplostim. Safety data identify hepatic laboratory abnormalities, rare thrombosis and marrow fibrosis in adult immune thrombocytopenia, and clonal evolution in severe aplastic anemia.</p><p><strong>Discussion: </strong>Endpoint heterogeneity, sponsor involvement, abstract-only evidence, and limited multiethnic data constrain cross-trial inference. Food markedly reduces exposure; cyclosporine interaction data are reassuring but imprecise.</p><p><strong>Conclusion: </strong>Use should follow local labels and disease guidelines, target clinically meaningful outcomes rather than platelet normalization, and include indication-specific hepatic, thrombotic, marrow, and discontinuation surveillance.</p>","PeriodicalId":13161,"journal":{"name":"Hematology","volume":"31 1","pages":"2755117"},"PeriodicalIF":2.0,"publicationDate":"2026-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149320704","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"XPO1 inhibitor selinexor suppresses homologous recombination by inhibiting E2F7 nuclear export in acute myeloid leukemia.","authors":"Chunli Xu, Dandan Wang, Ruiqi Chen, Xu Feng, Feng Cheng, Yu Chen","doi":"10.1080/16078454.2026.2664314","DOIUrl":"10.1080/16078454.2026.2664314","url":null,"abstract":"<p><strong>Objectives: </strong>Aberrant nucleocytoplasmic transport mediated by Exportin 1 (XPO1) contributes to leukemogenesis, yet the molecular basis underlying the limited efficacy of the XPO1 inhibitor Selinexor in acute myeloid leukemia (AML) remains unclear. This study aimed to define the role of XPO1 in AML and elucidate the mechanism by which Selinexor regulates homologous recombination (HR).</p><p><strong>Methods: </strong>Public AML datasets and patient samples were analyzed to assess XPO1 expression and clinical relevance. Functional assays evaluated the effects of XPO1 knockdown on AML cell proliferation, apoptosis, and cell cycle progression. Transcriptomic analysis, immunoprecipitation, subcellular fractionation, DNA damage assays, and direct HR functional assays were used to investigate Selinexor-mediated mechanisms. Drug interaction analyses assessed the combined effect of Selinexor and Mitoxantrone.</p><p><strong>Results: </strong>XPO1 was significantly overexpressed in AML, particularly in relapsed cases, and high expression was associated with poor prognosis. XPO1 knockdown suppressed proliferation, induced apoptosis, and caused cell cycle arrest. High XPO1 expression correlated with activation of the HR pathway. Mechanistically, Selinexor disrupted the interaction between XPO1 and the transcriptional repressor E2F7, resulting in nuclear retention of E2F7 and downregulation of BRCA1 and RAD51. E2F7 silencing reversed Selinexor-induced HR suppression and DNA damage. In addition, Selinexor synergized with Mitoxantrone to enhance DNA damage and apoptosis in AML cells.</p><p><strong>Discussion: </strong>E2F7-mediated HR inhibition is a key mechanism underlying Selinexor activity in AML.</p><p><strong>Conclusion: </strong>The XPO1-E2F7-HR axis represents a potential therapeutic vulnerability, supporting the rational combination of Selinexor with DNA-damaging agents to improve AML treatment outcomes.</p>","PeriodicalId":13161,"journal":{"name":"Hematology","volume":"31 1","pages":"2664314"},"PeriodicalIF":2.0,"publicationDate":"2026-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147770038","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
HematologyPub Date : 2026-12-31Epub Date: 2026-04-02DOI: 10.1080/16078454.2026.2647314
Joanna Bao-Ern Loh, Sangwook Kim, Richard Ward, Soodeh Sagheb, Andrew Binding, Kevin H M Kuo, Chris McIntosh, Kartik Jhaveri
{"title":"Machine learning in the prediction of liver iron concentration and iron chelation therapy adjustment.","authors":"Joanna Bao-Ern Loh, Sangwook Kim, Richard Ward, Soodeh Sagheb, Andrew Binding, Kevin H M Kuo, Chris McIntosh, Kartik Jhaveri","doi":"10.1080/16078454.2026.2647314","DOIUrl":"10.1080/16078454.2026.2647314","url":null,"abstract":"<p><strong>Objectives: </strong>Iron chelation therapy titration is managed by hematologists who monitor iron levels and adjust medication dosages to achieve patient outcomes. This study developed a machine learning (ML) algorithm to predict the liver iron concentration (LIC) and chelation therapy adjustments.</p><p><strong>Methods: </strong>This retrospective, single-centre cohort study included adult patients who underwent FerriScan MRI to obtain LIC for chelation therapy monitoring. Using an XgBoost-based ML framework, the proximal-time model (PTM) utilised clinical/drug, laboratory and MRI data features from one visit prior to the target visit, whereas the all-time model (ATM) utilised the data from all prior visits.</p><p><strong>Results: </strong>94 patients with 892 consecutive visits between January 2008 and November 2018 were included in this study. We assessed the prediction capabilities of the PTM and ATM in LIC, changes to chelation drug type and dosage changes. The PTM model was superior to the ATM model in all the experiments. When drug features were excluded, the CLICT model for predicting patient iron overload status improved to an AUROC of 0.83 [95% CI 0.75-0.91] for PTM; compared to an AUROC of 0.73 [95% CI 0.66-0.80] when drug features were included.For predicting changes in chelation type, the CLICT model showed AUROC of 0.83 [95% CIs 0.77-0.89] for PTM. There is high concordance of the agreement of hematologists with ML in not changing the chelation drug type.</p><p><strong>Discussion/conclusion: </strong>The ML model is a step toward creating a clinical decision support system tool for the prediction of LIC and iron chelation therapy adjustment in patients with haemoglobinopathies or hemolytic anemias.</p>","PeriodicalId":13161,"journal":{"name":"Hematology","volume":"31 1","pages":"2647314"},"PeriodicalIF":2.0,"publicationDate":"2026-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147591851","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
HematologyPub Date : 2026-12-31Epub Date: 2026-07-13DOI: 10.1080/16078454.2026.2702256
Ojan Ghodsi, Ali Ghasemi, Saleh Ahangari
{"title":"The role of von Willebrand factor in gastrointestinal angiodysplasia and obscure gi bleeding: a narrative review.","authors":"Ojan Ghodsi, Ali Ghasemi, Saleh Ahangari","doi":"10.1080/16078454.2026.2702256","DOIUrl":"https://doi.org/10.1080/16078454.2026.2702256","url":null,"abstract":"<p><strong>Objective: </strong>Gastrointestinal bleeding (GIB) is a major cause of morbidity in von Willebrand disease (vWD), most commonly resulting from angiodysplasia. Current obscure gastrointestinal bleeding (OGIB) algorithms are primarily anatomy-based and often overlook underlying hemostatic disorders, delaying diagnosis and promoting recurrent bleeding. This review summarizes current evidence on the molecular basis, diagnosis, and management of vWD-associated GIB and proposes a mechanism-oriented diagnostic framework.</p><p><strong>Methods: </strong>A comprehensive narrative review of experimental, translational, and clinical studies was conducted, focusing on inherited vWD, acquired von Willebrand syndrome (AvWS), gastrointestinal angiodysplasia, endothelial biology, and diagnostic and therapeutic strategies.</p><p><strong>Results: </strong>Deficiency or dysfunction of high-molecular-weight von Willebrand factor (vWF) multimers promotes angiodysplasia by disrupting Weibel-Palade body homeostasis, enhancing Ang-2/Tie2 and VEGF signaling, impairing integrin αvβ3 function, and fostering pro-inflammatory endothelial activation. Genetic and epigenetic modifiers, including FLI1, STXBP5, ABO blood group, and miR-24, further influence vascular susceptibility. Based on these mechanisms, we propose a four-stage diagnostic framework integrating bleeding assessment, platelet function screening, and targeted vWF testing with conventional endoscopic evaluation to facilitate earlier recognition of vWD/AvWS in patients with recurrent or obscure GIB. This strategy supports mechanism-based treatment combining hemostatic replacement therapies with selected anti-angiogenic approaches.</p><p><strong>Conclusion: </strong>vWD-associated GIB should be regarded as a systemic vascular-hemostatic disorder rather than an isolated structural gastrointestinal disease. Integrating hemostatic evaluation into OGIB pathways may improve diagnostic accuracy, reduce unnecessary procedures, and enable personalized management of patients with recurrent bleeding.</p>","PeriodicalId":13161,"journal":{"name":"Hematology","volume":"31 1","pages":"2702256"},"PeriodicalIF":2.0,"publicationDate":"2026-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148436651","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"The association between serum trace elements and iron deficiency anemia in children and adolescents: a systematic review and meta-analysis.","authors":"Maryam Mobasheri-Shiri, Sepehr Ramezanipour, Zahra Azizi, Faezeh Mobasheri-Shiri, Zeinab Karimi-Moghadam, Sina Kardeh, Mitra Abbasifard, Reza Tabrizi","doi":"10.1080/16078454.2026.2650058","DOIUrl":"10.1080/16078454.2026.2650058","url":null,"abstract":"<p><strong>Objectives: </strong>Iron deficiency anemia (IDA) remains the most prevalent form of anemia in children and adolescents globally. In addition to iron (Fe), other trace elements, such as zinc (Zn), copper (Cu), and magnesium (Mg), may influence hematopoiesis, yet the extent of their dysregulation in IDA remains unclear.</p><p><strong>Methods: </strong>We conducted a systematic review and meta-analysis of observational studies assessing the serum levels of Fe, Zn, Cu, and Mg in pediatric IDA populations. The literature was searched in PubMed, Scopus, Embase, and Web of Science up to January 2025. The data were standardized to consistent units (μmol/L), and pooled weighted mean differences (WMD) with 95% confidence intervals (CI) were calculated. Subgroup, sensitivity, and publication bias analyses were performed. The study protocol was registered online (PROSPERO number: CRD42024578704).</p><p><strong>Results: </strong>Eight articles encompassing twelve datasets and 1105 participants were included. Compared to controls, IDA patients had significantly lower levels of Fe (WMD: -13.07 μmol/L, 95% CI: -16.09 to -10.05), Zn (WMD: -4.33 μmol/L, 95% CI: -5.30 to -3.35), and Mg (WMD: -18.17 μmol/L, 95% CI: -21.00 to -15.33) but higher levels of Cu (WMD: 4.33 μmol/L, 95% CI: 2.21-6.46). High heterogeneity (<i>I</i>² > 95%) was noted for Fe, Zn, and Cu. Subgroup analyses confirmed consistent trends across age, gender, and geography.</p><p><strong>Conclusion: </strong>Pediatric IDA is associated with broad alterations in trace elements, highlighting potential roles for Fe, Zn, Cu, and Mg in the pathophysiology of anemia. These findings may inform comprehensive nutritional strategies in managing IDA.</p>","PeriodicalId":13161,"journal":{"name":"Hematology","volume":"31 1","pages":"2650058"},"PeriodicalIF":2.0,"publicationDate":"2026-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147591962","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"The correlation between cardiac T2*MRI and B-Type natriuretic peptides in patients with transfusion-dependent anemias and systemic iron overload: a systematic review and meta-analysis.","authors":"Mohamad Amin Kharaghani, Reza Samiee, Amirhossein Shahsavand, Shayan Forghani, Mahta Moradi, Tahereh Jangjoo Pirbazari, Elham Shahgholi","doi":"10.1080/16078454.2026.2644716","DOIUrl":"10.1080/16078454.2026.2644716","url":null,"abstract":"<p><strong>Objectives: </strong>Systemic iron overload in transfusion-dependent anemias leads to progressive myocardial iron accumulation, a major cause of morbidity and mortality. This study evaluated the relationship between cardiac T2* magnetic resonance imaging (MRI) values and natriuretic peptide levels in patients with systemic iron overload.</p><p><strong>Methods: </strong>Cardiac T2* MRI magnetic resonance imaging (MRI) is the gold standard for assessing myocardial iron, but it is costly and not widely available. B-type natriuretic peptides (BNP and NT-proBNP), which reflect myocardial stress, may offer a practical biomarker alternative. This systematic review and meta-analysis evaluated the relationship between cardiac T2* MRI values and natriuretic peptide levels in patients with systemic iron overload. Nine studies involving 783 patients were included in the systematic review, and pooled analyses were performed using data from seven studies.</p><p><strong>Results: </strong>Pooled data from seven studies showed a moderate inverse correlation between T2* values and natriuretic peptide levels (r = -0.30, 95% CI -0.51 to -0.06), indicating higher peptide levels with greater myocardial iron deposition. Patients with cardiac iron overload (T2* < 20 ms) had significantly higher peptide levels (standardized mean difference = -0.71, 95% CI -1.32 to -0.11), with pooled mean concentrations of 321.1 (95% CI 248.3-393.9) compared with 179.0 (95% CI 134.3-223.6) in those without cardiac iron overload (T2* > 20 ms).</p><p><strong>Discussion: </strong>These findings suggest that natriuretic peptide levels reflect myocardial stress associated with cardiac iron burden and may provide clinically relevant information on myocardial iron overload.</p><p><strong>Conclusion: </strong>Although natriuretic peptides cannot replace cardiac MRI, they may serve as accessible, low-cost adjunct biomarkers for screening, monitoring, and early warning of myocardial iron overload, particularly where MRI is limited. Further prospective studies are warranted to validate their role in longitudinal assessment and risk prediction.</p>","PeriodicalId":13161,"journal":{"name":"Hematology","volume":"31 1","pages":"2644716"},"PeriodicalIF":2.0,"publicationDate":"2026-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147456871","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}